Evidence map›Paper›PMID 27611943›Full record

ArticleOncotarget2016

Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer.

Nathan Bucay, Kirandeep Sekhon, Shahana Majid, Soichiro Yamamura, Varahram Shahryari, Z Laura Tabatabai, Kirsten Greene, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nathan BucayDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Kirandeep SekhonDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Shahana MajidDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Soichiro YamamuraDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Varahram ShahryariDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Z Laura TabatabaiDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Kirsten GreeneDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Yuichiro TanakaDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Rajvir DahiyaDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Guoren DengDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
Sharanjot SainiDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA, USA.
University of California, San Francisco · USSan Francisco VA Medical Center · US

Funding

MicroRNAs in the Progression and Metastisis of Prostate CancerR01CA138642 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DAHIYA, RAJVIR · 2010 to 2014
$2.6M
MicroRNAs in frequently deleted loci regulate prostate cancer EMT and metastasisR01CA177984 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI SAINI, SHARANJOT · 2014 to 2018
$1.9M
BLRD VA I01 BX001123BLRD VA IP1 BX001604NCI NIH HHS R01 CA138642NCI NIH HHS R01 CA177984
6 · The paper itself

Abstract

Genomic loss of chromosome (chr) 8p21 region, containing prostate-specific NKX3.1 gene, is a frequent alteration of the prostate cancer (PCa) oncogenome. We propose a novel, paradigm shifting hypothesis that this frequently deleted locus is also associated with a cluster of microRNA genes- miR-3622a/b- that are lost in PCa and play an important mechanistic role in progression and metastasis. In this study, we demonstrate the role of miR-3622b in prostate cancer. Expression analyses in a cohort of PCa clinical specimens and cell lines show that miR-3622b expression is frequently lost in prostate cancer. Low miR-3622b expression was found to be associated with tumor progression and poor biochemical recurrence-free survival. Further, our analyses suggest that miR-3622b expression is a promising prostate cancer diagnostic biomarker that exhibits 100% specificity and 66% sensitivity. Restoration of miR-3622b expression in PCa cell lines led to reduced cellular viability, proliferation, invasiveness, migration and increased apoptosis. miR-3622b overexpression in vivo induced regression of established prostate tumor xenografts pointing to its therapeutic potential. Further, we found that miR-3622b directly represses Epidermal Growth Factor Receptor (EGFR). In conclusion, our study suggests that miR-3622b plays a tumor suppressive role and is frequently downregulated in prostate cancer, leading to EGFR upregulation. Importantly, miR-3622b has associated diagnostic, prognostic and therapeutic potential. Considering the association of chr8p21 loss with poor prognosis, our findings are highly significant and support a novel concept that associates a long standing observation of frequent loss of a chromosomal region with a novel miRNA in prostate cancer.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 8AgedAnimalsApoptosisCell Line, TumorErbB ReceptorsGenes, Tumor SuppressorHumansMaleMiceMicroRNAsMiddle AgedProstate-Specific AntigenProstatic NeoplasmsEGFR protein, humanErbB ReceptorsMicroRNAsProstate-Specific Antigenchr8p21EGFRmiR-3622bprostate cancertumor suppressor

Identifiers

PMID27611943
PMCPMC5342560
OpenAlexW2520601168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.